Mechanics of Ibrutinib induced CLL cell death
bloodjournal.hematologylibr...
This mostly for doctors, you'll need a New England Journal of Medicine subscription to read it. It's the first good description of Ibrutinib resistance mutations I've found.
Here is the link to the full NEJM paper on resistance
Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLLIbrutinib resistance mutations often arise early, suggesting potential as a cue for alternative therapy
ASH 2018: Dr. Chadi Nabhan on the Cost of Ibrutinib vs. Chemo vs Chemoimmunotherapy in CLL and on way too much chemo being used.
Trouble Getting Insurance Approval for Ibrutinib in the US?
